Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan B King

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
JAMA Network Open|July 14, 2022
Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)Jordana B Cohen, Zachary A Marcum, Chong Zhang, et al.
Journal of the American Heart Association|April 26, 2019
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research NetworkAlanna M Chamberlain, Yan Gong, Kathryn McAuliffe Shaw, et al.
Hypertension (Dallas, Tex. : 1979)|December 15, 2022
Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention TrialCatherine G Derington, Adam P Bress, Andrew E Moran, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
The New England Journal of Medicine|August 24, 2017
Cost-Effectiveness of Intensive versus Standard Blood-Pressure ControlAdam P Bress, Brandon K Bellows, Jordan B King, et al.
Diabetes Care|August 11, 2017
Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized TrialAdam P Bress, Jordan B King, Kathryn E Kreider, et al.
Hypertension (Dallas, Tex. : 1979)|July 2, 2019
Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINTCatherine G Derington, Tyler H Gums, Adam P Bress, et al.
Plos One|April 23, 2021
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US VeteransCatherine G Derington, Jordana B Cohen, April F Mohanty, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
JAMA Network Open|July 14, 2022
Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)Jordana B Cohen, Zachary A Marcum, Chong Zhang, et al.
Journal of the American Heart Association|April 26, 2019
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research NetworkAlanna M Chamberlain, Yan Gong, Kathryn McAuliffe Shaw, et al.
Hypertension (Dallas, Tex. : 1979)|December 15, 2022
Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention TrialCatherine G Derington, Adam P Bress, Andrew E Moran, et al.
JAMA Network Open|February 14, 2022
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin TreatmentWilliam S Weintraub, Deepak L Bhatt, Zugui Zhang, et al.
The New England Journal of Medicine|August 24, 2017
Cost-Effectiveness of Intensive versus Standard Blood-Pressure ControlAdam P Bress, Brandon K Bellows, Jordan B King, et al.
Diabetes Care|August 11, 2017
Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized TrialAdam P Bress, Jordan B King, Kathryn E Kreider, et al.
Hypertension (Dallas, Tex. : 1979)|July 2, 2019
Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINTCatherine G Derington, Tyler H Gums, Adam P Bress, et al.
Plos One|April 23, 2021
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US VeteransCatherine G Derington, Jordana B Cohen, April F Mohanty, et al.
Pageof 7